Freedom Investment Management Inc. Invests $296,000 in Tempus AI, Inc. (NASDAQ:TEM)

Freedom Investment Management Inc. purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 8,771 shares of the company's stock, valued at approximately $296,000.

A number of other institutional investors and hedge funds have also made changes to their positions in TEM. ARK Investment Management LLC increased its stake in Tempus AI by 132.1% during the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company's stock worth $186,343,000 after buying an additional 3,141,487 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Tempus AI by 166.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company's stock worth $109,352,000 after buying an additional 2,021,394 shares during the period. Nikko Asset Management Americas Inc. increased its stake in Tempus AI by 166.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company's stock worth $109,352,000 after buying an additional 2,021,394 shares during the period. Franklin Resources Inc. increased its stake in Tempus AI by 240.5% during the 4th quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company's stock worth $93,251,000 after buying an additional 1,950,862 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Tempus AI by 86,947.2% during the 4th quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company's stock worth $55,836,000 after buying an additional 1,651,996 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Stock Down 1.1 %

TEM stock traded down $0.60 during trading on Friday, hitting $52.90. The company had a trading volume of 8,979,690 shares, compared to its average volume of 5,649,576. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The firm has a 50-day moving average price of $49.92 and a 200-day moving average price of $50.48. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Activity at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 79,118 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $53.86, for a total transaction of $4,261,295.48. Following the transaction, the chief executive officer now owns 5,692,669 shares in the company, valued at approximately $306,607,152.34. The trade was a 1.37 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the transaction, the chief accounting officer now owns 57,237 shares in the company, valued at $3,434,220. The trade was a 19.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,584,252 shares of company stock worth $272,870,580 in the last quarter. Company insiders own 27.60% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on TEM shares. Morgan Stanley upped their target price on shares of Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. BTIG Research started coverage on shares of Tempus AI in a report on Monday, April 21st. They set a "buy" rating and a $60.00 price target for the company. William Blair reaffirmed a "market perform" rating on shares of Tempus AI in a report on Tuesday, February 25th. Needham & Company LLC reaffirmed a "buy" rating and set a $70.00 price target on shares of Tempus AI in a report on Thursday. Finally, Piper Sandler decreased their price target on Tempus AI from $70.00 to $55.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.08.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.